Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) was down 7.1% on Thursday . The company traded as low as C$1.30 and last traded at C$1.31. Approximately 101,594 shares traded hands during trading, an increase of 34% from the average daily volume of 75,629 shares. The stock had previously closed at C$1.41.

Cardiol Therapeutics Trading Down 7.1%

The company has a market capitalization of C$145.96 million, a PE ratio of -3.20 and a beta of 1.21. The company has a fifty day simple moving average of C$1.39 and a 200-day simple moving average of C$1.51. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. Analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.